Abu Dhabi 1.3m Population Study—Both Pfizer mRNA & China’s Sinopharm Vaccine Not Linked to Cardiovascular or Hematological Incidence

An Abu Dhabi-based global tech-enabled health company, M42 combines G42 Healthcare&rsquo;s unique medical and data-centric technologies and Mubadala Health&rsquo;s world-class patient services and state-of-the-art facilities to provide higher levels of personalized, precise and preventive care as reported by TrialSite earlier during the COVID-19 pandemic.&nbsp; Recently researcher Marco Pimentel, PhD (biomedical/medical engineering), Maaz Shaikh, MBBS, MPH Shadab Khan, PhD, MPH, and colleagues designed and conducted a retrospective cohort study covering 1.3 million individuals residing in Abu Dhabi, United Arab Emirates, who received 1.8 million doses of the inactivated BBIBP CorV (by SinoPharm) and mRNA-based BNT162b2 (Pfizer-BioNTech) vaccines between June 1, 2021, and June 30, 2022. Why this class of study?&nbsp; According to the team of authors, a combination of physicians, medical researchers and data scientists, the ubiquitous nature of the mass COVID-19 countermeasure response necessitates &ldquo;a need to understand their safety profile&rdquo; as reported in the journal Nature Communications.&nbsp; Are there differences in safety profile between the Chinese inactivated&nbsp; and the U.S. and Germany-based mRNA COVID-19 vaccines?&nbsp; Of particular concern to the M42 group: troubling cardiovascular signals plus hematological adverse events. 
TrialSite has featured M42 early in the pandemic, a Sino-Gulf/Emirates hybrid AI/analytics and medical venture now operating in 26 countries according to the venture&rsquo;s website.&nbsp; As Bloomberg reported in April of this year the firm found itself right in the middle of mounting tensions between the People&rsquo;s Republic of China and the United States and leaned to the side of the latter over the former.